Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2023 Oct 2;10:1673–1687. doi: 10.2147/JHC.S420614

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2023 Xiao et al.

This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).

PMC Copyright notice

Analysis of immune infiltration and immunotherapy between high- and low-risk groups. (A) The proportion of 22 immune cells in LIHC samples. (B) Discrepancies of immune cells between high- and low-risk groups. ns, not significant; *p<0.05; ** p<0.01; ***p<0.001; ****p<0.0001. (C) Comparison of 47 immune checkpoints expression between high- and low-risk groups. ns, not significant; *p<0.05; ** p<0.01; ***p<0.001; ****p<0.0001. (D and E) The discrepancies of immunophenscore (IPS) (D) and tumor immune dysfunction and exclusion (TIDE) score (E) between high- and low-risk groups. ns, not significant; *p<0.05; ** p<0.01. (F) Comparison of immune score, ESTIMATE score, stromal score, and tumor purity between high- and low-risk groups. *p < 0.05, **p < 0.01.

Abbreviation: ns, not significant.